International Journal of Gynecology & Obstetrics · 2009 · 30 citations · 22 references
MedicineOncologyPathologyGynecologic OncologySurgical OncologyTumor PathologyTumor MorphologyUterine PathologyClinicopathologic FeaturesEndometrial Stromal SarcomaEndometrioid NeoplasmsSarcoma ClassificationSarcoma PathologyUterine Carcinosarcoma
OBJECTIVE: To evaluate the clinicopathologic data and prognostic factors for patients with uterine sarcomas treated at a single institution, with special emphasis on malignant mixed müllerian tumors (MMMT). METHODS: Medical and anatomic pathology records were reviewed. Survival rates were analyzed using the Kaplan-Meier method. RESULTS: The study included 89 patients: 48.4% with MMMT; 22.4% with leiomyosarcomas; 20.2% with endometrial stromal sarcomas; and 9% with adenosarcomas. FIGO stages I, II, III, and IV were identified in 57.3%, 9.0%, 22.5%, and 7.8% of patients respectively. Event-free survival rates after 2, 5, and 10 years were 70%, 61%, and 55% respectively, with a median time of 90 months (95% CI, 41-140 months). Overall survival rates after 2, 5, and 10 years were 50%, 45%, and 39% respectively, with a median time of 43 months (95% CI, 3-83 months). Multivariate analysis showed that stage, histology, tumor size, and parity had an independent influence on overall survival. CONCLUSIONS: MMMT are the most aggressive tumors and their behavior strongly resembles that of high-grade endometrial adenocarcinoma. Prognostic factors affecting survival were stage, histology, tumor size, and parity.
22
World Health Organization classification of tumors
Paul Kleihues, Leslie H. Sobin · Cancer · 2000 · 2.4K citations · Full text
Aaron H. Wolfson, M. Brady, Thomas F. Rocereto et al. · Gynecologic Oncology · 2007 · 258 citations · Full text
Michael Callister, Lois M. Ramondetta, Anuja Jhingran et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 209 citations
Medicine, Gynecology, Oncology +14